VP4-2024: First-in-class PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 in Patients (pts) with Advanced Solid Tumors: First-in-human Phase I Study

X. Bai,Y. Chen,X. Liang,H. Wang,Y. Sun,Q. Chu,Y. Pan,J. Cui,J. Fang,W. Zhang,Q. Xu,J. Zhang,X. Liu,G. Dai,L. Kang,N. Li,M. Fang,H. Zhou,T. Liang

DOI: https://doi.org/10.1016/j.annonc.2024.05.540

IF: 51.769

2024-01-01

Annals of Oncology

Abstract:IBI363 has great potential to address unmet clinical need of immunotherapy (IO) resistant and cold tumors by blocking PD-1 checkpoint and cis-activating α-bias IL-2 to rejuvenate exhausted tumor-specific T cells.